An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
NCT ID: NCT02477826
Last Updated: 2025-10-30
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
2747 participants
INTERVENTIONAL
2015-08-05
2024-10-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
NCT02041533
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
NCT03215706
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
NCT06946797
An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy
NCT02538666
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy
NCT02864251
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A: Nivolumab
Nivolumab intravenously (IV) as specified
Nivolumab
Arm B: Nivolumab + Ipilimumab
Nivolumab + Ipilimumab IV as specified
Nivolumab
Ipilimumab
Arm C: Nivolumab + Platinum doublet chemotherapy
Nivolumab + Platinum doublet chemotherapy (IV) dose as specified
Nivolumab
Carboplatin
Cisplatin
Gemcitabine
Pemetrexed
Paclitaxel
Arm D: Platinum doublet chemotherapy
Chemotherapy administered on specified days of IV chemotherapy
Carboplatin
Cisplatin
Gemcitabine
Pemetrexed
Paclitaxel
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nivolumab
Ipilimumab
Carboplatin
Cisplatin
Gemcitabine
Pemetrexed
Paclitaxel
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects must have programmed death-ligand 1 (PD -L1) immunohistochemical (IHC) testing, with results, performed by the central lab during the Screening period
* Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1
* Measurable disease by CT or MRI per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) criteria
Exclusion Criteria
* Subjects with an active, known or suspected autoimmune disease are excluded
* Any positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV) indicating acute or chronic infection
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ono Pharmaceutical Co. Ltd
INDUSTRY
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Southern Cancer Center, Inc.
Mobile, Alabama, United States
Local Institution - 0017
San Francisco, California, United States
Local Institution - 0021
New Haven, Connecticut, United States
Local Institution - 0001
Atlanta, Georgia, United States
Local Institution - 0013
Marietta, Georgia, United States
Local Institution - 0004
Lexington, Kentucky, United States
Local Institution - 0115
St Louis, Missouri, United States
Local Institution - 0005
Buffalo, New York, United States
Local Institution - 0019
New York, New York, United States
Local Institution - 0014
Cleveland, Ohio, United States
Local Institution - 0009
Columbus, Ohio, United States
Local Institution - 0007
Allentown, Pennsylvania, United States
Local Institution - 0075
Langhorne, Pennsylvania, United States
Local Institution - 0299
Philadelphia, Pennsylvania, United States
Local Institution - 0012
Philadelphia, Pennsylvania, United States
Local Institution - 0015
Sayre, Pennsylvania, United States
Local Institution - 0008
Charleston, South Carolina, United States
Local Institution - 0080
Greenville, South Carolina, United States
Local Institution - 0010
Greenville, South Carolina, United States
Local Institution - 0020
Nashville, Tennessee, United States
Local Institution - 0306
Dallas, Texas, United States
Local Institution - 0003
Dallas, Texas, United States
Local Institution - 0102
Houston, Texas, United States
Local Institution - 0011
Salt Lake City, Utah, United States
Local Institution - 0074
Kennewick, Washington, United States
Local Institution - 0170
Berazategui, Buenos Aires, Argentina
Local Institution - 0171
Capital Federal, Buenos Aires, Argentina
Local Institution - 0172
Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
Local Institution - 0176
Ciudad de Buenos Aires, Buenos Aires, Argentina
Local Institution - 0296
Mar del Plata, Buenos Aires, Argentina
Local Institution - 0130
San Miguel de Tucumán, Tucumán Province, Argentina
Local Institution - 0268
Córdoba, , Argentina
Local Institution - 0272
Córdoba, , Argentina
Local Institution - 0297
Córdoba, , Argentina
Local Institution - 0177
Viedma, , Argentina
Local Institution - 0182
Garran, Australian Capital Territory, Australia
Local Institution - 0301
Blacktown, New South Wales, Australia
Local Institution - 0300
Gosford, New South Wales, Australia
Local Institution - 0045
Brisbane, Queensland, Australia
Local Institution - 0046
Elizabeth Vale, South Australia, Australia
Local Institution - 0043
Clayton, Victoria, Australia
Local Institution - 0042
Fitzroy, Victoria, Australia
Local Institution - 0180
Perth, Western Australia, Australia
Local Institution - 0040
Murdoch, , Australia
Local Institution - 0183
North Tamworth, , Australia
Local Institution - 0241
Graz, , Austria
Local Institution - 0240
Vienna, , Austria
Local Institution - 0239
Wels, , Austria
Local Institution - 0034
Charleroi, Hainaut, Belgium
Local Institution - 0121
Roeselare, West-Vlaanderen, Belgium
Local Institution - 0030
Edegem, , Belgium
Local Institution - 0031
Ghent, , Belgium
Local Institution - 0117
Hasselt, , Belgium
Local Institution - 0033
Sint-Niklaas, , Belgium
Local Institution - 0125
Salvador, Estado de Bahia, Brazil
Local Institution - 0124
Ijuí, Rio Grande do Sul, Brazil
Local Institution - 0123
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution - 0127
Barretos, São Paulo, Brazil
Local Institution - 0129
Rio de Janeiro, , Brazil
Local Institution - 0144
São Paulo, , Brazil
Local Institution - 0126
São Paulo, , Brazil
Local Institution - 0128
São Paulo, , Brazil
Local Institution - 0103
Edmonton, Alberta, Canada
Local Institution - 0290
St. John's, Newfoundland and Labrador, Canada
Local Institution - 0104
London, Ontario, Canada
Local Institution - 0122
Montreal, Quebec, Canada
Local Institution - 0106
Québec, Quebec, Canada
Local Institution - 0302
Québec, Quebec, Canada
Local Institution - 0107
Rimouski, Quebec, Canada
Local Institution - 0291
Sherbrooke, Quebec, Canada
Local Institution - 0292
Trois-Rivières, Quebec, Canada
Local Institution - 0174
Viña del Mar, Región de Valparaíso, Chile
Local Institution - 0173
Santiago, Santiago Metropolitan, Chile
Local Institution - 0131
Santiago, Santiago Metropolitan, Chile
Local Institution - 0380
Hefei, Anhui, China
Local Institution - 0313
Beijing, Beijing Municipality, China
Local Institution - 0315
Beijing, Beijing Municipality, China
Local Institution - 0316
Beijing, Beijing Municipality, China
Local Institution - 0314
Beijing, Beijing Municipality, China
Local Institution - 0365
Chongqing, Chongqing Municipality, China
Local Institution - 0364
Chongqing, Chongqing Municipality, China
Local Institution - 0378
Chongqing, Chongqing Municipality, China
Local Institution - 0322
Guangzhou, Guangdong, China
Local Institution - 0372
Guangzhou, Guangdong, China
Local Institution - 0319
Guanzhou, Guangdong, China
Local Institution - 0323
Haikou, Hainan, China
Local Institution - 0325
Haerbin, Heilongjiang, China
Local Institution - 0324
Zhengzhou, Henan, China
Local Institution - 0379
Zhengzhou, Henan, China
Local Institution - 0375
Wuhan, Hubei, China
Local Institution - 0362
Changsha, Hunan, China
Local Institution - 0347
Nanchang, Jiangxi, China
Local Institution - 0329
Changchun, Jilin, China
Local Institution - 0361
Changchun, Jilin, China
Local Institution - 0359
Shenyang, Liaoning, China
Local Institution - 0371
Xi'an, Shaanxi, China
Local Institution - 0333
Xi'an, Shan3xi, China
Local Institution - 0360
Qingdao, Shandong, China
Local Institution - 0336
Shanghai, Shanghai Municipality, China
Local Institution - 0334
Shanghai, Shanghai Municipality, China
Local Institution - 0376
Chengdu, Sichuan, China
Local Institution - 0373
Tianjin, Tianjin Municipality, China
Local Institution - 0340
Ürümqi, Xinjiang, China
Local Institution - 0343
Hangzhou, Zhejiang, China
Local Institution - 0370
Hangzhou, Zhejiang, China
Local Institution - 0342
Hangzhou, Zhejiang, China
Local Institution - 0328
Changsha, , China
Local Institution - 0341
Hangzhou, , China
Local Institution - 0345
Kunming, , China
Local Institution - 0337
Shanghai, , China
Local Institution - 0374
Shantou, , China
Local Institution - 0273
Pereira, Risaralda Department, Colombia
Local Institution - 0237
Bogotá, , Colombia
Local Institution - 0238
Bogotá, , Colombia
Local Institution - 0282
Medellín, , Colombia
Local Institution - 0112
Hradec Králové, , Czechia
Local Institution - 0113
Olomouc, , Czechia
Local Institution - 0111
Prague, , Czechia
Local Institution - 0232
Příbram, , Czechia
Local Institution - 0270
Oulu, , Finland
Local Institution - 0271
Turku, , Finland
Local Institution - 0222
Bron, Rhône, France
Local Institution - 0216
Angers, , France
Local Institution - 0229
Besançon, , France
Local Institution - 0283
Caen, , France
Local Institution - 0218
Créteil, , France
Local Institution - 0228
Limoges, , France
Local Institution - 0215
Marseille, , France
Local Institution - 0230
Paris, , France
Local Institution - 0227
Pessac, , France
Local Institution - 0223
Rennes, , France
Local Institution - 0225
Rouen, , France
Local Institution - 0217
Saint-Herblain, , France
Local Institution - 0221
Saint-Priest-en-Jarez, , France
Local Institution - 0224
Strasbourg, , France
Local Institution - 0226
Toulon, , France
Local Institution - 0231
Magdeburg, Saxony-Anhalt, Germany
Local Institution - 0213
Bad Berka, , Germany
Local Institution - 0208
Berlin, , Germany
Local Institution - 0205
Essen, , Germany
Local Institution - 0210
Frankfurt, , Germany
Local Institution - 0211
Gera, , Germany
Local Institution - 0203
Großhansdorf, , Germany
Local Institution - 0209
Halle, , Germany
Local Institution - 0202
Heidelberg, , Germany
Local Institution - 0214
Hemer, , Germany
Local Institution - 0206
Immenstadt im Allgäu, , Germany
Local Institution - 0204
München, , Germany
Local Institution - 0201
Stuttgart, , Germany
Local Institution - 0212
Wiesbaden, , Germany
Local Institution - 0094
Athens, Attikí, Greece
Local Institution - 0095
Heraklion, , Greece
Local Institution - 0190
Neo Faliro, , Greece
Local Institution - 0101
Thessaloniki, , Greece
Local Institution - 0025
Budapest, , Hungary
Local Institution - 0024
Budapest, , Hungary
Local Institution - 0026
Mátraháza, , Hungary
Local Institution - 0054
Dublin, Dublin, Ireland
Local Institution - 0053
Beaumont, , Ireland
Local Institution - 0055
Galway, , Ireland
Local Institution - 0100
Limerick, , Ireland
Local Institution - 0187
Jerusalem, , Israel
Local Institution - 0186
Kfar Saba, , Israel
Local Institution - 0185
Petah Tikva, , Israel
Local Institution - 0184
Tel Litwinsky, , Israel
Local Institution - 0188
Ẕerifin, , Israel
Local Institution - 0083
Milan, Lombardy, Italy
Azienda Ospedaliera Moscati
Avellino, , Italy
Local Institution - 0179
Bergamo, , Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
Bologna, , Italy
Local Institution - 0084
Livorno, , Italy
Policlinico G. Martino
Messina, , Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, , Italy
Istituto Nazionale Tumori Fondazione Pascale
Napoli, , Italy
Local Institution - 0087
Perugia, , Italy
Ospedale Santa Maria delle Croci
Ravenna, , Italy
Ifo-Istituto Regina Elena
Roma, , Italy
Local Institution - 0089
Roma, , Italy
Local Institution - 0085
Terni, , Italy
Local Institution - 0153
Nagoya, Aichi-ken, Japan
Local Institution - 0152
Nagoya, Aichi-ken, Japan
Local Institution - 0260
Chiba, Chiba, Japan
Local Institution - 0148
Kashiwa-shi, Chiba, Japan
Local Institution - 0159
Matsuyama, Ehime, Japan
Local Institution - 0160
Fukuoka, Fukuoka, Japan
Local Institution - 0259
Kurume-shi, Fukuoka, Japan
Local Institution - 0255
Ota-shi, Gunma, Japan
Local Institution - 0258
Hiroshima, Hiroshima, Japan
Local Institution - 0163
Sapporo, Hokkaido, Japan
Local Institution - 0253
Sapporo, Hokkaido, Japan
Local Institution - 0252
Akashi-shi, Hyōgo, Japan
Local Institution - 0156
Kobe, Hyōgo, Japan
Local Institution - 0146
Kanazawa, Ishikawa-ken, Japan
Local Institution - 0161
Yokohama, Kanagawa, Japan
Local Institution - 0150
Yokohama, Kanagawa, Japan
Local Institution - 0275
Natori-shi, Miyagi, Japan
Local Institution - 0254
Sendai, Miyagi, Japan
Local Institution - 0145
Sendai, Miyagi, Japan
Local Institution - 0164
Niigata, Niigata, Japan
Local Institution - 0158
Kurashiki-shi, Okayama-ken, Japan
Local Institution - 0155
Hirakata-shi, Osaka, Japan
Local Institution - 0154
Osaka, Osaka, Japan
Local Institution - 0251
Osakasayama-shi, Osaka, Japan
Local Institution - 0257
Takatsuki-shi, Osaka, Japan
Local Institution - 0353
Hidaka-shi, Saitama, Japan
Local Institution - 0256
Kitaadachi-gun, Saitama, Japan
Local Institution - 0151
Sunto-gun, Shizuoka, Japan
Local Institution - 0147
Chuo-ku, Tokyo, Japan
Local Institution - 0149
Koto-ku, Tokyo, Japan
Local Institution - 0278
Shinjuku-ku, Tokyo, Japan
Local Institution - 0157
Wakayama, Wakayama, Japan
Local Institution - 0354
Ube-shi, Yamaguchi, Japan
Local Institution - 0165
Okayama, , Japan
Local Institution - 0162
Tokyo, , Japan
Local Institution - 0287
Beirut, , Lebanon
Local Institution - 0286
Beirut, , Lebanon
Local Institution - 0197
Guadalajara, Jalisco, Mexico
Local Institution - 0191
Zapopan, Jalisco, Mexico
Local Institution - 0196
Df, Mexico City, Mexico
Local Institution - 0193
Mexico City, Mexico City, Mexico
Local Institution - 0267
Morelia, Michoacán, Mexico
Local Institution - 0277
Monterrey, Nuevo León, Mexico
Local Institution - 0198
Cuautitlán, State of Mexico, Mexico
Local Institution - 0303
Mérida, Yucatán, Mexico
Local Institution - 0192
Chihuahua City, , Mexico
Local Institution - 0195
San Luis Potosí City, , Mexico
Local Institution - 0236
San Luis Potosí City, , Mexico
Local Institution - 0194
Toluca, , Mexico
Local Institution - 0036
Amsterdam, , Netherlands
Local Institution - 0189
Amsterdam, , Netherlands
Local Institution - 0169
Breda, , Netherlands
Local Institution - 0037
Rotterdam, , Netherlands
Local Institution - 0039
Veldhoven, , Netherlands
Local Institution - 0262
Lima, , Peru
Local Institution - 0263
Lima, , Peru
Local Institution - 0350
Lima, , Peru
Local Institution - 0261
Lima, , Peru
Local Institution - 0351
Lima, , Peru
Local Institution - 0060
Bydgoszcz, , Poland
Local Institution - 0058
Gdansk, , Poland
Local Institution - 0063
Gdynia, , Poland
Local Institution - 0072
Gliwice, , Poland
Local Institution - 0057
Lodz, , Poland
Local Institution - 0059
Warsaw, , Poland
Local Institution - 0070
Wroclaw, , Poland
Local Institution - 0167
Craiova, , Romania
Local Institution - 0250
Floreşti, , Romania
Local Institution - 0166
Romania, , Romania
Local Institution - 0284
Sector 2, , Romania
Local Institution - 0137
Chelyabinsk, , Russia
Local Institution - 0142
Kazan', , Russia
Local Institution - 0022
Moscow, , Russia
Local Institution - 0028
Saint Petersburg, , Russia
Local Institution - 0049
Saint Petersburg, , Russia
Local Institution - 0027
Saint Petersburg, , Russia
Local Institution - 0143
Ufa, , Russia
Local Institution - 0264
Pretoria, Gauteng, South Africa
Local Institution - 0234
Sandton, Gauteng, South Africa
Local Institution - 0233
Saxonwold, Johannesburg, Gauteng, South Africa
Local Institution - 0305
Vereeniging, , South Africa
Local Institution - 0136
Seongnam-si, Kyǒnggi-do, South Korea
Local Institution - 0249
Cheongju-si, , South Korea
Local Institution - 0133
Gangnam-gu, , South Korea
Local Institution - 0132
Seoul, , South Korea
Local Institution - 0135
Seoul, , South Korea
Local Institution - 0064
Majadahonda, Madrid, Spain
Local Institution - 0066
Barcelona, , Spain
Local Institution - 0067
Barcelona, , Spain
Local Institution - 0065
Madrid, , Spain
Local Institution - 0069
Seville, , Spain
Local Institution - 0068
Valencia, , Spain
Local Institution - 0243
Basel, , Switzerland
Local Institution - 0246
Chur, , Switzerland
Local Institution - 0244
Lausanne, , Switzerland
Local Institution - 0245
Winterthur, , Switzerland
Local Institution - 0139
Taichung, , Taiwan
Local Institution - 0138
Taipei, , Taiwan
Local Institution - 0140
Taipei, , Taiwan
Local Institution - 0310
Taipei, , Taiwan
Local Institution - 0141
Taoyuan, , Taiwan
Local Institution - 0266
Middlesbrough, Cleveland, United Kingdom
Local Institution - 0098
London, Greater London, United Kingdom
Local Institution - 0099
Southampton, Hampshire, United Kingdom
Local Institution - 0118
Leicester, Leicestershire, United Kingdom
Local Institution - 0265
Birmingham, , United Kingdom
Local Institution - 0051
Cambridgeshire, , United Kingdom
Local Institution - 0109
Edinburgh, , United Kingdom
Local Institution - 0097
London, , United Kingdom
Local Institution - 0050
London, , United Kingdom
Local Institution - 0119
Surrey, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Peters S, Paz-Ares LG, Reck M, Carbone DP, Brahmer JR, Borghaei H, Lu S, O'Byrne KJ, John T, Ciuleanu TE, Schenker M, Bernabe Caro R, Nishio M, Cobo M, Lee JS, Zurawski B, Pluzanski A, Aoyama T, Tschaika M, Devas V, Grootendorst DJ, Ramalingam SS. Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis. J Thorac Oncol. 2025 Jan;20(1):94-108. doi: 10.1016/j.jtho.2024.09.1439. Epub 2024 Oct 4.
Mason M, Lapuente-Santana O, Halkola AS, Wang W, Mall R, Xiao X, Kaufman J, Fu J, Pfeil J, Banerjee J, Chung V, Chang H, Chasalow SD, Lin HY, Chai R, Yu T, Finotello F, Mirtti T, Mayranpaa MI, Bao J, Verschuren EW, Ahmed EI, Ceccarelli M, Miller LD, Monaco G, Hendrickx WRL, Sherif S, Yang L, Tang M, Gu SS, Zhang W, Zhang Y, Zeng Z, Das Sahu A, Liu Y, Yang W, Bedognetti D, Tang J, Eduati F, Laajala TD, Geese WJ, Guinney J, Szustakowski JD, Vincent BG, Carbone DP. A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer. J Transl Med. 2024 Feb 21;22(1):190. doi: 10.1186/s12967-023-04705-3.
Brahmer JR, Lee JS, Ciuleanu TE, Bernabe Caro R, Nishio M, Urban L, Audigier-Valette C, Lupinacci L, Sangha R, Pluzanski A, Burgers J, Mahave M, Ahmed S, Schoenfeld AJ, Paz-Ares LG, Reck M, Borghaei H, O'Byrne KJ, Gupta RG, Bushong J, Li L, Blum SI, Eccles LJ, Ramalingam SS. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. J Clin Oncol. 2023 Feb 20;41(6):1200-1212. doi: 10.1200/JCO.22.01503. Epub 2022 Oct 12.
Reck M, Ciuleanu TE, Lee JS, Schenker M, Audigier-Valette C, Zurawski B, Linardou H, Otterson GA, Salman P, Nishio M, de la Mora Jimenez E, Lesniewski-Kmak K, Albert I, Ahmed S, Syrigos K, Penrod JR, Yuan Y, Blum SI, Nathan FE, Sun X, Moreno-Koehler A, Taylor F, O'Byrne KJ. First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1. J Thorac Oncol. 2021 Apr;16(4):665-676. doi: 10.1016/j.jtho.2020.12.019. Epub 2021 Jan 21.
Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.
Reck M, Schenker M, Lee KH, Provencio M, Nishio M, Lesniewski-Kmak K, Sangha R, Ahmed S, Raimbourg J, Feeney K, Corre R, Franke FA, Richardet E, Penrod JR, Yuan Y, Nathan FE, Bhagavatheeswaran P, DeRosa M, Taylor F, Lawrance R, Brahmer J. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. Eur J Cancer. 2019 Jul;116:137-147. doi: 10.1016/j.ejca.2019.05.008. Epub 2019 Jun 11.
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O'Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-003630-23
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CA209-227
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.